-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 4, 2022, the clinical application for LL-10, a new class 1 chemical drug, submitted by Shandong New Times Pharmaceutical Co.
, Ltd.
, was undertaken by CDE
.
In 2021, the company has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly in the field of anti-tumor therapy
.
, Ltd.
, was undertaken by CDE
.
In 2021, the company has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly in the field of anti-tumor therapy
.
Table 1: New drugs declared for clinical trials by Shandong New Era Pharmaceuticals since 2021
Source: CDE official website
According to data from Minet.
com, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti- tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
It has successfully ascended the throne of the TOP1 category, and the growth rate in the first half of 2021 is as high as 15.
30%
.
com, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti- tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
It has successfully ascended the throne of the TOP1 category, and the growth rate in the first half of 2021 is as high as 15.
30%
.
The 2021 edition of the National Medical Insurance List has added 22 anti-tumor and immunomodulatory drugs, including Orbrutinib Tablets, Fluzoparib Capsules, Donafenib Tosylate Tablets, Fumetinib Mesylate Tablets, etc.
1 New drugs have become big winners, and with the escort of medical insurance, the market outbreak is just around the corner
.
1 New drugs have become big winners, and with the escort of medical insurance, the market outbreak is just around the corner
.
Shandong New Era Pharmaceuticals has 3 Class 1 new drugs declared and approved for clinical use in 2021, involving multiple myeloma, advanced solid tumors, lymphoma and other popular fields.
Among them, recombinant humanized anti-BCMA/CD3 bispecific for injection Antibodies have attracted much market attention
.
Among them, recombinant humanized anti-BCMA/CD3 bispecific for injection Antibodies have attracted much market attention
.
Table 2: Products approved for listing in Shandong New Era in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, a total of 7 products of Shandong New Era will be approved for listing, all of which will be reported for production according to the new classification and will be regarded as over-evaluation
.
Among them, axitinib tablets, oxaliplatin injection and epirubicin hydrochloride injection were won in the field of anti-tumor and immunomodulatory agents
.
In 2020, the sales of axitinib tablets in public medical institutions in China will be close to 300 million yuan, and Shandong New Era Pharmaceutical is the first imitation in China; oxaliplatin is a large variety with a value of over 3 billion yuan, and epirubicin Sales are also more than 800 million yuan
.
.
Among them, axitinib tablets, oxaliplatin injection and epirubicin hydrochloride injection were won in the field of anti-tumor and immunomodulatory agents
.
In 2020, the sales of axitinib tablets in public medical institutions in China will be close to 300 million yuan, and Shandong New Era Pharmaceutical is the first imitation in China; oxaliplatin is a large variety with a value of over 3 billion yuan, and epirubicin Sales are also more than 800 million yuan
.
Note: The original text has been deleted
Source: CDE official website, Minet data
The review data statistics are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
On January 4, 2022, the clinical application for LL-10, a new class 1 chemical drug, submitted by Shandong New Times Pharmaceutical Co.
, Ltd.
, was undertaken by CDE
.
In 2021, the company has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly in the field of anti-tumor therapy
.
, Ltd.
, was undertaken by CDE
.
In 2021, the company has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly in the field of anti-tumor therapy
.
Table 1: New drugs declared for clinical trials by Shandong New Era Pharmaceuticals since 2021
Source: CDE official website
According to data from Minet.
com, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti- tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
It has successfully ascended the throne of the TOP1 category, and the growth rate in the first half of 2021 is as high as 15.
30%
.
com, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti- tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
It has successfully ascended the throne of the TOP1 category, and the growth rate in the first half of 2021 is as high as 15.
30%
.
The 2021 edition of the National Medical Insurance List has added 22 anti-tumor and immunomodulatory drugs, including Orbrutinib Tablets, Fluzoparib Capsules, Donafenib Tosylate Tablets, Fumetinib Mesylate Tablets, etc.
1 New drugs have become big winners, and with the escort of medical insurance, the market outbreak is just around the corner
.
1 New drugs have become big winners, and with the escort of medical insurance, the market outbreak is just around the corner
.
Shandong New Era Pharmaceuticals has 3 Class 1 new drugs declared and approved for clinical use in 2021, involving multiple myeloma, advanced solid tumors, lymphoma and other popular fields.
Among them, recombinant humanized anti-BCMA/CD3 bispecific for injection Antibodies have attracted much market attention
.
Among them, recombinant humanized anti-BCMA/CD3 bispecific for injection Antibodies have attracted much market attention
.
Table 2: Products approved for listing in Shandong New Era in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, a total of 7 products of Shandong New Era will be approved for listing, all of which will be reported for production according to the new classification and will be regarded as over-evaluation
.
Among them, axitinib tablets, oxaliplatin injection and epirubicin hydrochloride injection were won in the field of anti-tumor and immunomodulatory agents
.
In 2020, the sales of axitinib tablets in public medical institutions in China will be close to 300 million yuan, and Shandong New Era Pharmaceutical is the first imitation in China; oxaliplatin is a large variety with a value of over 3 billion yuan, and epirubicin Sales are also more than 800 million yuan
.
.
Among them, axitinib tablets, oxaliplatin injection and epirubicin hydrochloride injection were won in the field of anti-tumor and immunomodulatory agents
.
In 2020, the sales of axitinib tablets in public medical institutions in China will be close to 300 million yuan, and Shandong New Era Pharmaceutical is the first imitation in China; oxaliplatin is a large variety with a value of over 3 billion yuan, and epirubicin Sales are also more than 800 million yuan
.
Note: The original text has been deleted
Source: CDE official website, Minet data
The review data statistics are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
On January 4, 2022, the clinical application for LL-10, a new class 1 chemical drug, submitted by Shandong New Times Pharmaceutical Co.
, Ltd.
, was undertaken by CDE
.
In 2021, the company has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly in the field of anti-tumor therapy
.
, Ltd.
, was undertaken by CDE
.
In 2021, the company has submitted a total of 8 new drug clinical applications with acceptance numbers, of which 5 have been approved, mainly in the field of anti-tumor therapy
.
Table 1: New drugs declared for clinical trials by Shandong New Era Pharmaceuticals since 2021
Source: CDE official website
According to data from Minet.
com, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti- tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
It has successfully ascended the throne of the TOP1 category, and the growth rate in the first half of 2021 is as high as 15.
30%
.
hospital hospital hospital tumor tumor tumorcom, in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) terminals, the sales volume of anti- tumor and immunomodulatory agents in 2020 has exceeded 160 billion yuan.
It has successfully ascended the throne of the TOP1 category, and the growth rate in the first half of 2021 is as high as 15.
30%
.
The 2021 edition of the National Medical Insurance List has added 22 anti-tumor and immunomodulatory drugs, including Orbrutinib Tablets, Fluzoparib Capsules, Donafenib Tosylate Tablets, Fumetinib Mesylate Tablets, etc.
1 New drugs have become big winners, and with the escort of medical insurance, the market outbreak is just around the corner
.
1 New drugs have become big winners, and with the escort of medical insurance, the market outbreak is just around the corner
.
Shandong New Era Pharmaceuticals has 3 Class 1 new drugs declared and approved for clinical use in 2021, involving multiple myeloma, advanced solid tumors, lymphoma and other popular fields.
Among them, recombinant humanized anti-BCMA/CD3 bispecific for injection Antibodies have attracted much market attention
.
Among them, recombinant humanized anti-BCMA/CD3 bispecific for injection Antibodies have attracted much market attention
.
Table 2: Products approved for listing in Shandong New Era in 2021
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In 2021, a total of 7 products of Shandong New Era will be approved for listing, all of which will be reported for production according to the new classification and will be regarded as over-evaluation
.
Among them, axitinib tablets, oxaliplatin injection and epirubicin hydrochloride injection were won in the field of anti-tumor and immunomodulatory agents
.
In 2020, the sales of axitinib tablets in public medical institutions in China will be close to 300 million yuan, and Shandong New Era Pharmaceutical is the first imitation in China; oxaliplatin is a large variety with a value of over 3 billion yuan, and epirubicin Sales are also more than 800 million yuan
.
.
Among them, axitinib tablets, oxaliplatin injection and epirubicin hydrochloride injection were won in the field of anti-tumor and immunomodulatory agents
.
In 2020, the sales of axitinib tablets in public medical institutions in China will be close to 300 million yuan, and Shandong New Era Pharmaceutical is the first imitation in China; oxaliplatin is a large variety with a value of over 3 billion yuan, and epirubicin Sales are also more than 800 million yuan
.
Note: The original text has been deleted
Source: CDE official website, Minet data
The review data statistics are as of January 6.
If there are any mistakes or omissions, please correct me
.
If there are any mistakes or omissions, please correct me
.
